Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term. A trial ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its other GLP-1 products.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Pfizer abandoned the development of danuglipron and plans to focus its efforts on GIPR candidates and other earlier obesity programs.